These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Clinical experience of chemotherapy with S-1/CDDP for highly-advanced gastric cancer].
    Author: Uchima Y, Kosaka K, Kimura K, Okita Y, Sim JK, Aomatsu N, Hirata K, Lee WH, Lee T, Nishii T, Tei S, Takeuchi K.
    Journal: Gan To Kagaku Ryoho; 2010 Jul; 37(7):1287-90. PubMed ID: 20647711.
    Abstract:
    BACKGROUND: We evaluated the efficacy and safety of chemotherapy with S-1/CDDP for advanced and recurrent gastric cancer at Fuchu Hospital. METHODS: The participants were 24 patients treated at our hospital. S-1 was given orally at 80 mg/m/2 for days 1-21, and 60 mg/m2 of CDDP was administered on day 8, followed by a 2-week rest period, within a 5-week course. RESULTS: Results were rated as a partial response in 12 cases and a stable response in 4 cases. The response rate was 50% (12/24), and median survival time was 273 days. The total incidence of grade 3 or greater adverse reactions including leucopenia, neutropenia, anemia, general fatigue, and eruption, was 25% (6/24). CONCLUSION: The combination of S-1/CDDP therapy appears to be highly efficacious and safe and showed promise as a useful treatment strategy, even in an outpatient clinic.
    [Abstract] [Full Text] [Related] [New Search]